Kymera Therapeutics: Peers

The FY2025 (Dec) proxy of Kymera Therapeutics names 18 peer companies for pay. Among Kymera Therapeutics and these peers, CEO pay was 7th highest of 10 and total shareholder return was 7th highest of 10.

7th highest of 10in Kymera Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$4.8M$33.3M

7th highest of 10in Kymera Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:

$20$625

Pay peer group, FY2025 (Dec) proxy

Scholar Rock Holding
Viking Therapeutics
Revolution Medicines
Protagonist Therapeutics
Immunovant
IDEAYA Biosciences
Vera Therapeutics
Beam Therapeutics
Denali Therapeutics
ApogeeTherapeuticsNot disclosedNot disclosed
ArcellxNot disclosedNot disclosed
ArvinasNot disclosedNot disclosed
Avidity BiosciencesNot disclosedNot disclosed
BiohavenNot disclosedNot disclosed
Dyne TherapeuticsNot disclosedNot disclosed
ImmunityBioNot disclosedNot disclosed
NuvalentNot disclosedNot disclosed
VaxcyteNot disclosedNot disclosed
18 companies

Changes by year

No proxy on file names a change to the peer group.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.